Clinical Trials for Hyperthyroidism

Source: ClinicalTrials.gov — U.S. National Library of Medicine — A database of privately and publicly funded clinical studies conducted around the world (U.S. National Library of Medicine, public domain).

This page lists clinical trials related to Hyperthyroidism from the ClinicalTrials.gov database.

Trial Summary

• Total studies: 50
• Recruiting: 18
• Active, not recruiting: 9
• Completed: 11
• Other: 12

Results are refreshed periodically and may not reflect the most current information available from ClinicalTrials.gov.

Recruiting Trials

NCT00001159 — Natural History of Thyroid Function Disorders

Participants in this study will be patients diagnosed with or suspected to have a thyroid function disorder. These conditions may include: hypothyroidism, hyperthyroidism, thyroid hormone resistance, Graves’ Dermopathy, and thyroid-stimulating hormone (TSH) secreting pituitary adenomas.

The main purpose of this study is to further understand the natural history, clinical presentation, and gene…

NCT06401044 — A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease

The primary objective of Part A of this study is to investigate the safety and tolerability of AMG 732 after single subcutaneous (SC) doses. The primary objective of Part B of this study is to investigate the efficacy of AMG 732 in participants with Thyroid Eye Disease (TED) after multiple SC doses.

NCT06727604 — A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves’ Disease

This is a study to assess the efficacy, safety, and tolerability of IMVT-1402 in adult participants with Graves’ disease (GD) who are hyperthyroid despite antithyroid drug (ATD) treatment.

The primary objective of this study is to evaluate the efficacy of IMVT-1402 versus placebo as assessed by T3 (total triiodothyronine [T3] or free triiodothyronine [FT3]), free thyroxine (FT4), thyroid-s…

NCT07557810 — Efficacy of Thermal Ablation Combined With Antithyroid Drugs in the Treatment of Primary Hyperthyroidism

Hyperthyroidism is a clinical syndrome caused by excessive production of thyroid hormones, leading to accelerated metabolism and increased excitability of multiple organ systems. Patients commonly present with polyphagia, weight loss, palpitations, and sweating. Primary hyperthyroidism is a common endocrine disorder traditionally treated with anti-thyroid drugs (ATD), radioactive iodine (¹³¹I),…

NCT07018323 — A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves’ Disease

This is a multi-center, global, randomized, double-blind, placebo-controlled Phase 2b study to assess the efficacy, safety, and tolerability of IMVT-1402 in adult participants with Graves’ disease (GD) who are hyperthyroid despite antithyroid drug (ATD) treatment.

NCT06989918 — MHB018A Treatment in Patients With Active Thyroid Eye Disease

The primary objective of this study is to investigate the efficacy, safety, and tolerability of MHB018A, a humanized anti-IGF1R antibody, administered q4W for 6 months, in comparison to placebo, in the treatment of participants suffering from active TED.

NCT06980649 — Study of BHV-1300 in Graves’ Disease

The purpose of this study is to determine if BHV-1300 is a safe treatment in participants with Graves’ Disease and to explore its effect on disease-specific biomarkers.

NCT06984627 — A Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves’ Disease

This is a parallel group, Phase 2, 2-arm study to measure the treatment effect and safety of rilzabrutinib dose 1 or rilzabrutinib dose 2 in participants with Graves’ disease, with and without Graves’ orbitopathy, aged 18 years or older.

Study details include:

• Screening period (up to 4 weeks).
• Treatment period (up to 16 weeks).
• Follow-up period (4 weeks). The number of visits will be up…

NCT07305818 — NEXUS Study: A Study to Test Single and Multiple Doses of MER511 Given to Adults With Graves’ Disease

The purpose of this study is to evaluate how well MER511 is tolerated and what side effects may occur in adults who have Graves’ disease. The study drug will be administered either intravenously (into a vein in the arm) or subcutaneously (under the skin).

Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body.

NCT07017907 — Evaluating an AI Tool for Detecting Thyrotoxic States

This observational study aims to evaluate the performance of a software-based medical device, Glandy HYPER, in detecting the thyrotoxic state in patients with hyperthyroidism. The device utilizes heart rate data collected from commercially available wearable devices and compares it with thyroid function test results. The study will enroll patients diagnosed with Graves’ disease, monitoring thei…

NCT07400757 — Statin and Vitamin D Treatment in Patients With Thyroid Eye Disease

The goal of this clinical trial is to learn whether statin therapy and vitamin D supplementation can modify disease activity in patients with active thyroid eye disease. The study will also evaluate the safety of these treatments. The main questions it aims to answer are:

• Does statin therapy change disease activity, as measured by changes in the Clinical Activity Score (CAS) and proptosis? *…

NCT07547930 — Tofacitinib for Glucocorticoid-Resistant Moderate-to-Severe Thyroid Eye Disease

Thyroid Eye Disease (TED), also known as Graves’ orbitopathy, is an autoimmune condition that causes inflammation and tissue expansion behind the eyes, leading to bulging eyes (proptosis), double vision, and pain. Currently, intravenous glucocorticoids (steroids) are the standard first-line treatment. However, approximately 20-30% of patients do not respond to steroids, or cannot tolerate their…

NCT07438405 — An Open-label, Rollover Trial to Evaluate the Efficacy and Safety of AMG 732 in Participants With Thyroid Eye Disease

The main objective of this trial is to assess the efficacy of AMG 732 in participants with thyroid eye disease (TED) who are defined as primary nonresponders or relapsed during the safety follow-up in the parent trial (NCT06401044).

NCT07597200 — A Clinical Study of Cizutamig in Thyroid Eye Disease

The purpose of this study is to evaluate the safety, tolerability, PK, PD, immunogenicity, and preliminary clinical activity of cizutamig in patients with thyroid eye disease (TED).

NCT07570316 — A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves’ Disease

The main purpose of this study is to look at how efgartigimod affects thyroid function in adults with Graves’ Disease (GD). The study will also check whether efgartigimod is safe and well tolerated. It will look at how efgartigimod is distributed and eliminated in the body, how it changes antibody levels, and how the immune system responds to it.

The study consists of a part A double-blinded t…

NCT07596849 — A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves’ Disease.

The main purpose of this study is to look at how efgartigimod affects thyroid function in adults with Graves’ Disease (GD). The study will also check whether efgartigimod is safe and well tolerated. It will look at how efgartigimod is distributed and eliminated in the body, how it changes antibody levels, and how the immune system responds to it.

The study consists of a part A double-blinded t…

NCT07682896 — Evaluation of YB-101 for Safety, Tolerability, Pharmacokinetics, and Efficacy in Graves’ Disease

This study is being conducted to look at the effect YB-101 has on thyroid function. This study will also evaluate how safe and well tolerated YB-101 is and how it is distributed through the body.

The study consists of a part 1, blinded treatment period, and a part 2 double-blinded treatment period. Participants will receive YB-101 or Placebo subcutaneously. Participants who participate in Part…

NCT07661056 — Study to Determine if BHV-1300 is Effective and Safe in Adults With Graves’ Disease

The purpose of this study is to evaluate the efficacy and safety of BHV-1300 in adult participants with Graves’ disease who are actively hyperthyroid

Active, Not Recruiting

NCT05987423 — Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease

The purpose of this study is to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of subcutaneous (SC) satralizumab, a recombinant, humanized anti-interleukin-6 (IL-6) receptor monoclonal antibody, in participants with thyroid eye disease (TED).

NCT06106828 — A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease

The purpose of this study is to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of subcutaneous (SC) satralizumab, a recombinant, humanized anti-interleukin-6 (IL-6) receptor monoclonal antibody, in participants with thyroid eye disease (TED).

NCT06921304 — BASE-DIET: a Study on Nutritional Intervention in Patients With Graves’ Disease

The goal of this clinical trial is to determine whether a structured dietary-nutritional intervention can prevent excessive weight regain and improve body composition and lifestyle habits in adults recently diagnosed with Graves’ disease (Basedow’s disease).

The main questions it aims to answer are:

• Can a dietary intervention prevent patients from regaining more than 1 kg above their pre-di…

NCT06088979 — A Study to Investigate Efficacy and Safety of TOUR006 in Participants 18 to 80 Years of Age With Thyroid Eye Disease

Phase 2b trial of TOUR006 in Thyroid Eye Disease (TED) to evaluate 20mg and 50mg doses against placebo given by a subcutaneous injection every eight weeks to TED patients who are in the active inflammatory phase of disease.

NCT06248619 — A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease

The study consists of a randomized double-masked, placebo-controlled, parallel-group, multicenter trial with an optional open-label treatment period for proptosis non-responders who complete the Double-masked Treatment Period.

NCT06625398 — An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED)

This is a clinical trial assessing the efficacy, safety, and tolerability of an investigational drug, VRDN-003, in participants with chronic Thyroid Eye Disease (TED).

NCT06625411 — An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED)

This is a clinical trial assessing the efficacy, safety, and tolerability of an investigational drug, VRDN-003, in participants with active Thyroid Eye Disease (TED).

NCT06557850 — A Trial Investigating Lu AG22515 in Adult Participants With Moderate-to-Severe Thyroid Eye Disease

This trial will evaluate the effects of Lu AG22515 in adult men and women with moderate-to-severe thyroid eye disease (TED). TED is an autoimmune condition closely related to Graves’ Disease.

In people with TED, the healthy tissue behind and around the eye becomes inflamed and swollen. One of the key symptoms of TED is proptosis (bulging eyes). The main goal of this trial is to learn whether t…

NCT06812325 — A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)

This is a clinical trial assessing the safety and tolerability of an investigational drug, VRDN-003, in participants with Thyroid Eye Disease (TED).

Not Yet Recruiting

NCT07622368 — A Study of IBI3031 in Participants With Thyroid Eye Disease

This is a multicenter, randomized, double-masked, placebo-controlled, single/multiple-dose-escalation trial conducted in Chinese participants with Thyroid Eye Disease (TED), aiming to evaluate the safety and tolerability of IBI3031 administered via subcutaneous or intravenous injection.

NCT07623837 — Clinical Validation of AI-Based Quantitative Eye Movement Analysis From Smartphone 9-Gaze Videos (Glandy EOM)

This prospective, multicenter, multinational observational study evaluates the clinical validity of an AI-based quantitative eye movement analysis system (Glandy EOM) that analyzes smartphone-recorded 9-gaze videos. Approximately 200 adults per site with suspected or confirmed ocular motility abnormalities will undergo a single study visit consisting of a standard clinical 9-gaze examination, a…

NCT07623993 — Prospective Observational Study of Smartphone-Based AI Self-Monitoring During Non-Surgical Treatment for Thyroid Eye Disease (THYROSCOPE)

This prospective observational study evaluates the feasibility and clinical utility of a smartphone-based artificial intelligence (AI) self-monitoring system in adults with thyroid eye disease (TED) undergoing non-surgical treatment. Eligible participants will use their own smartphones and the study application (Glandy) to perform at least weekly home monitoring consisting of a symptom question…

NCT07594912 — Teprotumumab N01 Versus Methylprednisolone After Urgent Orbital Decompression for Dysthyroid Optic Neuropathy

This study aims to evaluate the efficacy and safety of sequential Teprotumumab N01 compared with intravenous methylprednisolone (IVMP) after urgent orbital decompression in patients with dysthyroid optic neuropathy (DON).

NCT07622108 — Treatment of Active Thyroid Eye Disease With MHB018A in a Randomized, Placebo-Controlled Study

The primary objective of this study is to evaluate the efficacy of MHB018A injection compared with placebo in participants with active moderate-to-severe TED.

NCT07622121 — Treatment of Chronic Thyroid Eye Disease With MHB018A

The primary objective of this study is to evaluate the efficacy of MHB018A injection compared with placebo in participants with chronic moderate-to-severe TED.

NCT07620405 — Open-Label Extension Study of MHB018A in Patients With Thyroid Eye Disease

This is a multicenter, open-label extension (OLE) study of MHB018A in subjects with moderate-to-severe TED.

Enrolling by Invitation

NCT07544290 — Autoimmune Hyperthyroidism in Prepubertal Children

The investigators propose a multicenter retrospective study to assess clinical, biochemical, and auxological characteristics at diagnosis and during follow-up in a cohort of Caucasian pediatric patients diagnosed with autoimmune hyperthyroidism before puberty. These prepubertal patients will be compared with a control group of post-pubertal patients with Graves’ disease.

This study aims to enh…

NCT07286006 — A Long-Term Extension Study of IMVT-1402 in Adult Participants With Graves’ Disease (GD)

This is a long-term extension study that will rollover participants completing feeder studies IMVT-1402-2502 (NCT06727604) or IMVT-1402-2503 (NCT07018323) to evaluate the efficacy and safety of IMVT-1402 in adult participants with GD. Eligible participants will be assigned to 1 of 3 study groups (Groups A, B and C) based on their GD status at the completion of their respective feeder study.

Completed Trials

NCT06367517 — Tocilizumab in Corticosteroid-Resistant Graves’ Orbitopathy (Thyroid Eye Disease)

The aim of this study is to evaluate the efficacy and safety of Tocilizumab as second/third line treatment in patients with Active Moderate-to-Severe Corticosteroid-Resistant Thyroid Eye Disease.

NCT04662190 — Evaluation of the Efficacy and Safety of 3D Printing for Orbital Surgery.

This is a multicentric, randomized, single-blinded clinical trial to evaluate the efficacy and safety of 3D printing for the planification and simulation of orbital decompression surgery for thyroid-associated orbitopathy.

NCT05524571 — Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease

To evaluate the efficacy of batoclimab 680 milligrams (mg) subcutaneous (SC) once a week (QW) for 12 weeks followed by 340 mg SC QW for 12 weeks versus placebo on proptosis responder rate at Week 24.

NCT06126783 — A Multicenter, Open-label Extension Study Evaluating the Efficacy and Safety of IBI311 in Subjects With Thyroid Eye Disease

A multicenter, open-label extension study evaluating the efficacy and safety of IBI311 in subjects with thyroid eye disease

NCT06179875 — An Open-label Study (OLE) for Non-responders of VRDN-001-101 (NCT05176639) and VRDN-001-301 (NCT06021054)

The investigational drug, VRDN-001, is a monoclonal antibody that inhibits the activity of a cell surface receptor called insulin-like growth factor-1 receptor (IGF-1R). Inhibition of IGF-1R may help to reduce the inflammation and associated tissue swelling that occurs in patients with thyroid eye disease (TED). The primary objectives of this clinical trial are to provide open-label access to V…

NCT06384547 — A Randomized, Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED)

The investigational drug, VRDN-001, is a monoclonal antibody that inhibits the activity of a cell surface receptor called insulin-like growth factor-1 receptor (IGF-1R). Inhibition of IGF-1R may help to reduce the inflammation and associated tissue swelling that occurs in patients with thyroid eye disease (TED). The primary objective of this clinical trial is to evaluate the safety and tolerabi…

NCT07164079 — Rubus Sanctus (Wild Blackberry) Root Extract as a Dietary Supplement for Graves’ Disease

The aim of this single-blind, randomized, experimental study was to investigate the effect of Rubus sanctus root extract, which has antioxidant properties, added to the routine diet of patients with Graves’ disease on the prognosis of the disease.

The study sample included patients who presented to the Endocrinology and Metabolic Diseases Outpatient Clinic of Muğla Sıtkı Koçman University Trai…

NCT07688824 — The Effect of SPU on Hormonal and Cardiometabolic Factors

The study examines the immediate effect of soleus pushup exercise on cardiometabolic and hormonal functions among hypothyroid patients.

NCT07155668 — A Safety, Tolerability and Pharmacokinetics Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)

This is a clinical trial assessing the safety, tolerability and pharmacokinetics (PK) of an investigational drug, VRDN-003, in participants with TED (Thyroid Eye Disease)

NCT07066241 — Virtual Reality on Stress, Pain Levels in Patients With Hyperthyroidism Undergoing Biopsy

This study aims to investigate the effects of virtual reality on stress, pain levels and vital signs in patients diagnosed with hyperthyroidism who underwent fine needle biopsy.

NCT07610460 — Thyroid Uptake Quantification Validation on a Three-dimensional (3D) Cadmium-Zinc-Telluride (CZT) New Generation Gamma Camera

Thyroid scintigraphy using technetium-99m (99mTc) pertechnetate is traditionally performed using planar imaging to estimate thyroid uptake. Recent developments in quantitative SPECT/CT allow direct activity quantification from three-dimensional tomographic acquisitions. The aim of this study was to evaluate the accuracy of thyroid uptake quantification obtained from 3D SPECT/CT compared with co…

Other (Terminated)

NCT04737330 — A Study of the Efficacy and Safety of Secukinumab 300 mg in Patients With Thyroid Eye Disease (TED)

Thyroid eye disease (TED) is a rare autoimmune, inflammatory disorder of the orbit and represents the most common extra-thyroidal manifestation of Graves’ disease (GD). Several lines of evidence suggest an important role of interleukin-17A (IL-17A) in the pathogenesis of TED; increased levels of IL-17A have been detected in the serum and tears of patients with TED and IL-17A levels correlate wi…

NCT05517447 — Extension Study to Assess Batoclimab in Participants With Thyroid Eye Disease

This is a 2-cohort (observational and treatment cohort) extension study for participants completing feeder studies (IMVT-1401-3201 or IMVT-1401-3202). The observational cohort will assess the durability of proptosis response of feeder studies off treatment. The treatment cohort will evaluate the efficacy of batoclimab as assessed by proptosis responder rate.

NCT06467435 — Evaluation of K9 in Subjects With Thyroid Eye Disease (TED)

The study is comprised of two cohorts. Cohort 1 will examine pharmacokinetics of K9 in 3 healthy volunteers over 24 hours. This cohort has been completed. Cohort 2 will involve up to 10 patients with TED. Patients will receive oral K9 BID for up to 24 weeks and will be followed up to a total of 26 weeks with a primary endpoint of safety.